Attempted treatment of fulminant viral hepatitis with human fibroblast interferon

F. Milazzo; G. M. Vigevani; M. Almaviva; M. Galli; R. Esposito; A. Lazzarin; F. Caredda; P. Crocchiolo; M. Moroni; A. Cargnel; M. C. Perna; P. G. Fassio; G. Gavazzeni; A. Pugliese; P. A. Tovo

doi:10.1007/BF01642872

Attempted treatment of fulminant viral hepatitis with human fibroblast interferon

F. Milazzo, G. M. Vigevani, M. Almaviva, M. Galli, R. Esposito, A. Lazzarin, F. Caredda, P. Crocchiolo, M. Moroni, A. Cargnel, M. C. Perna, P. G. Fassio, G. Gavazzeni, A. Pugliese, P. A. Tovo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

β-interferon was administered by intravenous infusion to 16 patients affected with fulminant hepatitis B virus infection in third or fourth-grade coma. Ten patients presented a superinfection or a co-infection due to the delta (δ)-agent. None had detectable interferon (IFN) activity before therapy was begun. Besides fever, no significant side-effects were observed during treatment. Both the IFN-treated group as well as the "historical" control group, made up of 70 cases of fulminant virus hepatitis, not treated with IFN and observed during a previous ten year-period, received supportive therapy; survival rates were similar in both groups. Furthermore, the presence or absence of the δ-agent did not appear to affect survival rates significantly.

Original language	English
Pages (from-to)	130-133
Number of pages	4
Journal	Infection
Volume	13
Issue number	3
DOIs	https://doi.org/10.1007/BF01642872
Publication status	Published - May 1985

ASJC Scopus subject areas

Microbiology (medical)
Immunology

Access to Document

10.1007/BF01642872

Fingerprint Dive into the research topics of 'Attempted treatment of fulminant viral hepatitis with human fibroblast interferon'. Together they form a unique fingerprint.

Cite this

Milazzo, F., Vigevani, G. M., Almaviva, M., Galli, M., Esposito, R., Lazzarin, A., Caredda, F., Crocchiolo, P., Moroni, M., Cargnel, A., Perna, M. C., Fassio, P. G., Gavazzeni, G., Pugliese, A., & Tovo, P. A. (1985). Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection, 13(3), 130-133. https://doi.org/10.1007/BF01642872

Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. / Milazzo, F.; Vigevani, G. M.; Almaviva, M.; Galli, M.; Esposito, R.; Lazzarin, A.; Caredda, F.; Crocchiolo, P.; Moroni, M.; Cargnel, A.; Perna, M. C.; Fassio, P. G.; Gavazzeni, G.; Pugliese, A.; Tovo, P. A.

In: Infection, Vol. 13, No. 3, 05.1985, p. 130-133.

Research output: Contribution to journal › Article

@article{7a86503ecf1942d9b823716a9905ca2c,

title = "Attempted treatment of fulminant viral hepatitis with human fibroblast interferon",

abstract = "β-interferon was administered by intravenous infusion to 16 patients affected with fulminant hepatitis B virus infection in third or fourth-grade coma. Ten patients presented a superinfection or a co-infection due to the delta (δ)-agent. None had detectable interferon (IFN) activity before therapy was begun. Besides fever, no significant side-effects were observed during treatment. Both the IFN-treated group as well as the {"}historical{"} control group, made up of 70 cases of fulminant virus hepatitis, not treated with IFN and observed during a previous ten year-period, received supportive therapy; survival rates were similar in both groups. Furthermore, the presence or absence of the δ-agent did not appear to affect survival rates significantly.",

author = "F. Milazzo and Vigevani, {G. M.} and M. Almaviva and M. Galli and R. Esposito and A. Lazzarin and F. Caredda and P. Crocchiolo and M. Moroni and A. Cargnel and Perna, {M. C.} and Fassio, {P. G.} and G. Gavazzeni and A. Pugliese and Tovo, {P. A.}",

year = "1985",

month = may,

doi = "10.1007/BF01642872",

language = "English",

volume = "13",

pages = "130--133",

journal = "Infection",

issn = "0300-8126",

publisher = "Urban und Vogel GmbH",

number = "3",

}

TY - JOUR

T1 - Attempted treatment of fulminant viral hepatitis with human fibroblast interferon

AU - Milazzo, F.

AU - Vigevani, G. M.

AU - Almaviva, M.

AU - Galli, M.

AU - Esposito, R.

AU - Lazzarin, A.

AU - Caredda, F.

AU - Crocchiolo, P.

AU - Moroni, M.

AU - Cargnel, A.

AU - Perna, M. C.

AU - Fassio, P. G.

AU - Gavazzeni, G.

AU - Pugliese, A.

AU - Tovo, P. A.

PY - 1985/5

Y1 - 1985/5

N2 - β-interferon was administered by intravenous infusion to 16 patients affected with fulminant hepatitis B virus infection in third or fourth-grade coma. Ten patients presented a superinfection or a co-infection due to the delta (δ)-agent. None had detectable interferon (IFN) activity before therapy was begun. Besides fever, no significant side-effects were observed during treatment. Both the IFN-treated group as well as the "historical" control group, made up of 70 cases of fulminant virus hepatitis, not treated with IFN and observed during a previous ten year-period, received supportive therapy; survival rates were similar in both groups. Furthermore, the presence or absence of the δ-agent did not appear to affect survival rates significantly.

AB - β-interferon was administered by intravenous infusion to 16 patients affected with fulminant hepatitis B virus infection in third or fourth-grade coma. Ten patients presented a superinfection or a co-infection due to the delta (δ)-agent. None had detectable interferon (IFN) activity before therapy was begun. Besides fever, no significant side-effects were observed during treatment. Both the IFN-treated group as well as the "historical" control group, made up of 70 cases of fulminant virus hepatitis, not treated with IFN and observed during a previous ten year-period, received supportive therapy; survival rates were similar in both groups. Furthermore, the presence or absence of the δ-agent did not appear to affect survival rates significantly.

UR - http://www.scopus.com/inward/record.url?scp=0021871109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021871109&partnerID=8YFLogxK

U2 - 10.1007/BF01642872

DO - 10.1007/BF01642872

M3 - Article

C2 - 3897068

AN - SCOPUS:0021871109

VL - 13

SP - 130

EP - 133

JO - Infection

JF - Infection

SN - 0300-8126

IS - 3

ER -